- Trials with a EudraCT protocol (6)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
6 result(s) found for: Pencil.
Displaying page 1 of 1.
EudraCT Number: 2012-003817-32 | Sponsor Protocol Number: LOLA-Merz:WMDHP39937 | Start Date*: 2013-01-08 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: Brain muscle axis during treatment of hepatic encephalopathy with L-ornithine L-aspartate | |||||||||||||
Medical condition: Hepatic Encephalopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002329-27 | Sponsor Protocol Number: ETLAS-2 | Start Date*: 2020-12-10 | ||||||||||||||||
Sponsor Name:Herlev Gentofte Hospital | ||||||||||||||||||
Full Title: Improving cerebral blood flow and cognition in patient with cerebral small vessel disease. The ETLAS-2 Trial. | ||||||||||||||||||
Medical condition: Cerebral small vessel disease and stroke. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003002-28 | Sponsor Protocol Number: CRIT124DDE01 | Start Date*: 2005-10-31 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: A 7 week multicenter, double-blind, randomized, placebo-controlled cross-over evaluation of the efficacy and safety of a modified-release oral dosage form of methylphenidate-HCl, Ritalin LA® (20 mg... | |||||||||||||
Medical condition: attention deficit hyperactivity disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004539-36 | Sponsor Protocol Number: 16NC06 | Start Date*: 2020-05-19 | ||||||||||||||||
Sponsor Name:Great Ormond Street Hospital for Children NHS Foundation Trust | ||||||||||||||||||
Full Title: Study of Montelukast In Children with Sickle Cell Disease (SMILES) | ||||||||||||||||||
Medical condition: Sleep-disordered breathing | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003730-25 | Sponsor Protocol Number: SBT20-102 | Start Date*: 2017-02-14 | |||||||||||
Sponsor Name:Stealth Bio Therapeutics Inc | |||||||||||||
Full Title: A Two Part Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SBT-020 in Patients with Early Stage Huntington’s Disease. | |||||||||||||
Medical condition: Huntington's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018285-23 | Sponsor Protocol Number: 18102009 | Start Date*: 2010-06-04 | ||||||||||||||||
Sponsor Name:King's College London [...] | ||||||||||||||||||
Full Title: Effect of active vitamin D treatment on arterial stiffness and albuminuria in patients with type 2 diabetes and stage 3 chronic kidney disease | ||||||||||||||||||
Medical condition: Diabetic kidney disease. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
